Rachel is partnering with sales, marketing and Pall’s technology teams to build company prominence as a preferred partner for the development and manufacturing of virus-based therapeutics with a focus on Gene Therapy. In addition to supporting global customers and building high level networks, Rachel is supporting various internal cross-functional activities including due diligence and new product development. Rachel has more than 20 years of experience in the field of scalable biologics and gene therapy manufacturing of therapeutic products, viral vector and proteins for gene therapy and biologics. She completed her Ph.D. in Food Engineering and Biotechnology at the Technion-Israel Institute of Technology, Israel. Rachel joined Pall in 2014 and currently serves as a process development services senior lab manager in charge of upstream and downstream process development, scale-up, and manufacturing support activities for the gene therapy and biologics markets. Prior to joining Pall, Rachel held several scientific and leadership roles at Microbiology & Molecular Genetics department at Harvard Medical School, SBH Sciences, Seahorse Biosciences, and Goodwin Biotechnology.